Render Target: SSR
Render Timestamp: 2025-02-06T19:13:23.801Z
Commit: 1bba917eefc12d62e72a522121e2774ffbd0ee36
XML generation date: 2024-08-01 14:14:09.846
Product last modified at: 2025-01-01T09:04:15.921Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77

PMEL/Melanoma gp100 (HMB45) Mouse mAb #38815

Filter:
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Mouse IgG1 kappa
    Application Key:
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    IHC Leica Bond 1:800 - 1:3200
    Immunohistochemistry (Paraffin) 1:400 - 1:1600

    Storage

    Supplied in 10 mM PBS containing 0.05% BSA and 0.05% sodium azide. Stable for 36 months when stored at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present, but will not interfere with antibody performance.

    Protocol

    Specificity / Sensitivity

    PMEL/Melanoma gp100 (HMB45) Mouse mAb recognizes endogenous levels of total PMEL/Melanoma gp100 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with extract of pigmented melanoma metastases from lymph nodes.

    Background

    PMEL/Melanoma gp100 is a type 1 transmembrane glycoprotein primarily expressed in pigment cells of the skin and eye, and overexpressed in more than 75% of human melanomas (1-3). It is involved in the transformation of melanosomes from stage I to stage II, forming the fibrillar matrix necessary for pigmentation of the cell (4). The synthesis and modification of PMEL/Melanoma gp100 is done in the endoplasmic reticulum (ER) and transferred to the Golgi complex where it is cleaved into two disulfide-linked subunits, Mα and Mβ. The cleavage of the large luminal Mα fragment is required for the formation of the fibrils that are the structure for melanin synthesis (5,6). The ability for PMEL/Melanoma gp100 to form functional amyloids makes it an interesting protein to study when looking at pathological amyloids in neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease (5,7). Due to melanocyte-restricted expression of this protein, PMEL/Melanoma gp100 is considered a tumor-associated antigen that can be targeted by immunotherapeutic approaches to treat melanoma (8-10).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.